Adults with #JIA #uveitis are still affected into adulthood. @Mara_Becker discusses visual outcomes #ACR21 https://t.co/ZBjw1CfSmv

Prof. Cornelia Weyand wonderfully summarizes the mechanisms behind the premature immune #aging phenotype in #RheumatoidArthritis leading to tissue #Inflammation 🔸defect in mitoDNA repair 🔸expanded rough ER 🔸⬇ protein myristoylation @RheumNow #ACR21 #RheumTwitter https://t.co/8cyqLscctB

Can you stop monitoring eyes in + ANA and/or pauciarticular pt who becomes an adult if no uveitis ever, in last 5 yrs, etc. When can we stop looking? #AVR21 @RheumNow https://t.co/1Ml1BuJD7Y

• Sheila Angeles-Han on Twitter: "Adults with #JIA #uveitis are still affect…

#ACR21 Year In Review highlighted the need to combat the root causes of socioeconomic disparities to improve functional status in #rheumatoid #arthritis @RheumNow https://t.co/MKgh7UEP8b https://t.co/Vg2jyfuDnf

• Socioeconomic Disparities in Functional Status in a National Sample of Patients…

Dr McDermott @jeffsparks on risk factors for RA-bronchiectasis. Seropositivity, older age at RA onset, and lower BMI⬆️risk. Abstr#0288 #ACR21 @RheumNow https://t.co/7d2ZVWLzn6

Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ

Dr Adachi presents ⬆️BMD gain with denosumab than risedronate in RA. Non-significant reduction in fractures (very small numbers) Interesting, but need to see fracture benefit in larger study to justify dmab as first line Abstr#0445 #ACR21 @RheumNow https://t.co/GgaS9JZGzb

Diabetes puts you at risk of cardiovascular disease, right? What about RA? Look at this graph and compare the pair. "already it was impossible to say which was which” - George Orwell, Animal Farm #ACR21 ABST0287 @RheumNow https://t.co/r0yaeC530l https://t.co/mKJhoyJ2Cn

• 20 Years Follow-up of Cardiovascular Event Risk in Rheumatoid Arthritis Compare…

Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX: 💠IFX-naive: improved disease activity 💠IFX-switched: maintained stable disease 💠No new safety concerns https://t.co/VGBicnq15w #ACR21 Abst#0817 @RheumNow

• Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis …

Interesting question came up: why would you change a RA patient from JAKi to JAKi? The main reason I can think of would be if the first JAKi worked a bit (but not enough to continue, or AEs got in the way). That would clearly favour to better survival #ACR21 ABST1442 @RheumNow https://t.co/kDiJVbJfit

• Richard Conway on Twitter: "JAK-pot registry-based study. Following JAKi f…

Loved this session on: Preclinical Rheumatoid Arthritis- Can we stop RA? As a patient advocate living with RA, my providers have always ran tests on my microbiome. The findings have correlated with my disease flares, and was a big trigger overall. #ACR21 @ACRheum Thank you! https://t.co/6hm6hr85JS

MRI Imaging in RA and SpA: Dr. Sheila Reyes ( @RHEUMarampa) Dr. Sheila Reyes discusses abstracts #0468 and #0469, presented at the #ACR21 annual meeting. https://t.co/MeVia60BNa https://t.co/WRgCifpioQ

• https://bit.ly/3o8Uexe

Alcohol and MTX don't go along! In a cohort of 1000+ early RA Factors associated w/ 1️⃣Nausea Female OR 2 🍺 Alcohol OR 1.44 DAS28CRP OR 1.16 2️⃣Alopecia Age OR 4.87 🍺 Alcohol OR 1.98 HAQ score OR 1.62 #Abst1444 #ACR21 @RheumNow https://t.co/zZG6aFR1SX